Medication regimen for prevention of drug resistance using enrofloxacin against Aeromonas hydrophilain crucian carp Carassius auratus
CSTR:
Author:
Affiliation:

1. College of Fisheries and Life Science, Shanghai Ocean University, Shanghai 201306, China; 2. Fisheries College of Sichuan Province, Chengdu 611730, China

Clc Number:

S942

  • Article
  • | |
  • Metrics
  • |
  • Reference [1]
  • |
  • Related
  • |
  • Cited by [0]
  • | |
  • Comments
    Abstract:

    The widespread use of antibiotics in aquaculture has led to increasing problems caused by bacterial resistance. Given this, there is an urgent need to develop a medication regimen that prevents the formation of drug resistant bacteria. We estimated a number of pharmacodynamic (including mutant prevent concentration and mutant selection window)and pharmacokinetic parameters for the antibiotic drug enrofloxacin. Our objective was to develop a medication regimen against hemorrhagic septicemia in crucian carp(The minimal inhibitory concentration (MIC) was 0.125 μg/mL, the post-antibiotic effect (PAE) of enrofloxacin on the pathogenic bacterial strains was observed up to (1.67±0.42) hmutant prevention concentration (MPC) was 1.125 μg/mL, and the mutant selection window was between 0.125 and 1.125 μg/mL. We developed integrated enrofloxacin concentration-time curves for the serum of crucian carp following administration of a range of doses. Enrofloxacin persisted in the serum at concentrations above the MPC for 5 h at a dose of 5 mg/kg; 9.5 h at a dose of 10 mg/kg, and 23 h at a dose of 20 mg/kg. The serum PK/PD parameters AUC24/MIC and /MIC were 137.22 and 15.05, respectively, at a dose of 5 mg/kg, 285.25 and 41.43, respectively, at a dose of 10 mg/kg, and 426.25 and 52.32, respectively, at a dose of 20 mg/kg.The drug remained in the plasma with a concentration >MPC for (24-PAE) h and AUC24/MICemorrhagic septicemia can be controlled , at intervals of 24 h.The proposed withdrawal time in crucian carp should not be less than 25 d. The methods described in this study also can be used for developing dose guidelines for other anti-bacterial drugs to prevent selection for drug-resistance.

    Reference

           樊丙新张玉千李长娥鲫鱼鳃霉病和出血病综合防治措施动物科学与动物医学, 2001, 18(1): 55−56.

           Dong Y, Zhao X, Domagala J, et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus [J]. Antimicrob Agents Chemother, 1999, 43: 1756−1758.

           Drlica K. Astrategy for fighting antibiotic resistance [J].ASM News, 2001, 67: 27−33.

           Liang B, Bai N, Cai Y, et al. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of staphylococcus aureus[J]. Antimicob Agents Chemother, 2011, 5(55): 24092412.

           梅清, 喻婷, 朱玉林, . 万古霉素单用及联合利福平或磷霉素对耐甲氧西林金黄色葡萄球菌防耐药突变浓度的研究[J]. 中国药理学通报, 2011, 27(7): 944947.

           Juan C R, Laura C, Manuela Z, et al. Mutant prevention concentration: a new tool for choosing treatment in nontuberculous mycobacterial infections [J]. Int J Antimicrob Agents, 2004, 24: 352356.

           Rafacla F, Marciane M. Mutant prevention concentration (MPC) of ciprofloxacin against Salmonella enteric of epidemic and pouty origin [J]. Curr Microbiol, 2011, 62: 628632.

           Blondeau J M, Borsos S, Blondeau L D, et al. Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica[J]. Vet Microbiol, 2012, 5: 16.

           李楠, 郭慧芝, 焦冉, . 草鱼的一种急性细菌性传染病病原的分离鉴定及致病性研究[J]. 水生生物学报, 2011, 35(6): 98986.

        谢家仪, 董光军, 刘振英. 扫描电镜的生物样品制备方法[J]. 电子显微学报, 2005, 24(4): 440

        National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: fourteenth informational supplement [M].Wayne, Pennsylvania: NCCLS, 2004: 1−159.

        戴自英临床抗菌药物学北京人民卫生出版社8.

        Sindelar G, Zhao X, Liew A, et al. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria[J]. Antimicob Agents Chemother, 2000, 44(12): .

        刘远飞氟喹诺酮类抗菌药后效应及其机制的研究哈尔滨东北农业大学.

        李慧芳, 殷军港, 刘永明. 鱼肉中喹诺酮类药物残留检测前处理方法的研究[J]. 中国渔业质量与标准, 2012, 1(2): 6266.

        Fang W, Zhou S, Yu H, Hu L, et al. Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in Scylla serrata following oral gavage at twosalinities[J]. Aquaculture, 2007, 272: 180187.

        钟妮娜, 汪开毓. 鲤鱼细菌性败血症及穿孔病病原菌与嗜水气单胞菌标准株特性的比较研究[J]. 四川农业大学学报, 2001, 19(1): 13.

        Samuelsen O B. Pharmacokinetics of quinolones in fish: A review[J]. Aquaculture, 2006, 255: 55 75

        Shi J. Integretion of pharmacokinetics and pharmacodynamics in antibacterial drug development and pharmacotherapy [J]. Chin J Clin Phamacol Ther, 2007, 12(10): 1099−1113.

        李运景邢洁陈文娟时间依赖性抗菌药与浓度依赖性抗菌药给药方案的优化中国现代药物应用, 2008, 24(2): 72−73.

        刘玉林, 王翔凌, 杨先乐, . 诺氟沙星在大黄鱼体内的药代动力学及残留研究[J]. 水产学报, 2007, 5(31): 655660.

        陆承平. 致病性嗜水气单胞菌及其所致鱼病综述[J]. 水产学报, 1992, 16(3): 282288.

        张雅斌, 刘艳辉, 张祚新, . 恩诺沙星在鲤鱼体内的药效学及药动学研究[J]. 大连水产学院学报, 2004, 4(19): 239242.

        杨亚军, 李剑勇, 李冰. 药动学—药效学结合模型及其在兽用抗菌药物中的应用[J]. 湖北农业科学, 2011, 50(1): 114121.

        侯卫东, 张雯雯, 陈宁. 抗菌药物防突变浓度与耐药突变选择窗的研究进展[J]. 河南畜牧兽医, 2012, 31(2): 911.

    Related
    Comments
    Comments
    分享到微博
    Submit
Get Citation

徐丽娟,权可艳,王浩,胡鲲,杨先乐,吕利群. 恩诺沙星控制嗜水气单胞菌性鲫败血症的防耐药用药方案[J]. Jounal of Fishery Sciences of China, 2013,[volume_no](3):635-643

Copy
Share
Article Metrics
  • Abstract:737
  • PDF: 0
  • HTML: 0
  • Cited by: 0
History
  • Online: May 30,2013
Article QR Code